Association between copy number variation of complement component C4 and Graves' disease

Table 4 Distribution of C4 polymorphisms in Graves' disease patients with or without Graves' ophthalmopathy

Variations	GO		P value, individual^a [OR (95%CI), individual]^c	P value^b	OR (95%CI)^d
	No, N (%)	Yes, N (%)
C4 CNV
4	196 (49.4)	118 (52.0)	0.561	0.396	(Reference)
< 4	92 (23.2)	42 (18.5)	0.188		0.978(0.614-1.558)
> 4	109 (27.5)	67 (29.5)	0.581		1.029(0.687-1.540)
*C4A* CNV
2	238 (39.9)	157 (69.2)	0.025 [1.436 (0.994-2.075)]	0.014	(Reference)
< 2	61 (15.4)	18 (7.9)	0.008 [0.590 (0.328-1.059)]		0.549 (0.303-0.998)
> 2	98 (24.7)	52 (22.9)	0.628		0.772 (0.509-1.169)
*C4B* CNV
2	229 (57.7)	148 (65.2)	0.074	0.186	(Reference)
< 2	97 (24.4)	46 (20.3)	0.276		0.806 (0.520-1.249)
> 2	71 (17.9)	33 (14.5)	0.316		0.697 (0.430-1.132)
C4 polymorphisms
A2B2	149 (37.5)	105 (46.3)	0.035 [1.283 (0.900-1.828)]	0.005	(Reference)
A2B1	53 (13.4)	25 (11.0)	0.451		0.796 (0.449-1.411)
A3B2	37 (9.3)	27 (11.9)	0.338		1.067 (0.596-1.912)
A2B3	29 (7.3)	15 (6.6)	0.871		0.734 (0.366-1.476)
A3B1	25 (6.3)	7 (3.1)	0.091		0.374 (0.146-0.960)
A1B2	28 (7.1)	6 (2.6)	0.026 [0.451(0.176-1.160)]		0.374 (0.153-1.056)
Other	65 (16.4)	40 (17.6)			0.894 (0.549-1.455)

Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
^aIndividual C4 CNVs and polymorphisms between GD patients with or without GO were evaluated by Fisher's exact test using 2 × 2 contingency tables.
^b CNV of C4, C4A and C4B between GD patients with or without GO were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without GO were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
^cORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.
^dORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.

ISSN: 1423-0127